About this trial
Patient Profile
participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery
Where’s this trial being run?
Bon Secours Cork, St Vincents University Hospital, and University Hospital Galway
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | MK-2870-012 |
|---|---|
| Number: | 24-58 |
| Full Title: | A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery |
| Principal Investigator: | Dr Janice Walsh |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Merck Sharp & Dohme LLC |
| Recruitment Started: |
Global: June 2024 Ireland: November 2024 |
| Global Recruitment Target: | 1530 |
|---|---|
| Ireland Recruitment Target: | 7 |